Literature DB >> 1584565

Management of giant retinal tears without scleral buckling. Use of radical dissection of the vitreous base and perfluoro-octane and intraocular tamponade.

A E Kreiger1, H Lewis.   

Abstract

The introduction of intraoperative perfluorocarbon liquids in the management of giant retinal tears has allowed exact anatomic reapposition of the retina and the giant retinal tear. Therefore, the authors managed 11 eyes with giant retinal tears and no proliferative vitreoretinopathy without scleral buckling. Maximum removal of the basal vitreous gel was performed in all cases, and perfluoro-octane was used intraoperatively to unfold the inverted posterior flap and reattach the retina completely. Endophotocoagulation was applied to the edges of the tear and perfluoropropane or silicone oil was used as an intraocular tamponade. Although 1 eye required reoperation for a redetachment from posterior proliferative vitreoretinopathy, all retinas were reattached with final visual acuity of 5/200 or better in 9 eyes. Eight additional major procedures were necessary in seven eyes: removal of silicone oil in four (with removal of perisilicone proliferation in three), repeat vitrectomy and membrane removal with photocoagulation twice in one eye, cataract extraction in one eye, and removal of a macular pucker in one eye. Four eyes required postoperative fluid-gas exchange and three eyes had tissue plasminogen activator injections into the anterior chamber for postoperative fibrin reactions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1584565     DOI: 10.1016/s0161-6420(92)31942-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  13 in total

1.  Outcome of surgery in patients with giant retinal tear: 10 years experience.

Authors:  K Ghasemi Falavarjani; S A Alemzadeh; M Modarres; S A Alemzadeh; M M Parvarash; M Naseripour; M Hashemi; M Robatmeili
Journal:  Eye (Lond)       Date:  2017-08-04       Impact factor: 3.775

2.  Vitrectomy with short term postoperative tamponade using perfluorocarbon liquid for giant retinal tears.

Authors:  M Sirimaharaj; C Balachandran; W C Chan; A P Hunyor; A A Chang; J Gregory-Roberts; A B Hunyor; T J Playfair
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

3.  Contact angles of substances used for internal tamponade in retinal detachment surgery.

Authors:  I M Fawcett; R L Williams; D Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-07       Impact factor: 3.117

4.  The management of wound-related complications in pars plana vitrectomy.

Authors:  A E Kreiger
Journal:  Trans Am Ophthalmol Soc       Date:  1994

5.  Silicone oil versus gas tamponade for giant retinal tear-associated fovea-sparing retinal detachment: a comparison of outcome.

Authors:  P J Banerjee; A Chandra; P Petrou; D G Charteris
Journal:  Eye (Lond)       Date:  2017-08-11       Impact factor: 3.775

6.  Management of giant retinal tears with vitrectomy and perfluorocarbon liquid postoperatively as a short-term tamponade.

Authors:  M A Mikhail; G Mangioris; R M Best; S McGimpsey; W C Chan
Journal:  Eye (Lond)       Date:  2017-08-11       Impact factor: 3.775

7.  Retinal Tamponades: Current Uses and Future Technologies.

Authors:  Avnish Deobhakta; Richard Rosen
Journal:  Curr Ophthalmol Rep       Date:  2020-07-04

8.  Pars plana vitrectomy combined with scleral buckle versus pars plana vitrectomy for giant retinal tear.

Authors:  Mario Gutierrez; Jose L Rodriguez; Diego Zamora-de La Cruz; Mariana Aracely Flores Pimentel; Aida Jimenez-Corona; Linda C Novak; Rene Cano Hidalgo; Federico Graue
Journal:  Cochrane Database Syst Rev       Date:  2019-12-16

9.  Giant retinal tears after prior pars plana vitrectomy: management strategies and outcomes.

Authors:  Marco A Gonzalez; Harry W Flynn; William E Smiddy; Thomas A Albini; Audina M Berrocal; Paul Tenzel
Journal:  Clin Ophthalmol       Date:  2013-08-27

10.  The outcome of surgical management for giant retinal tear more than 180°.

Authors:  Sherif A Dabour
Journal:  BMC Ophthalmol       Date:  2014-06-27       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.